[Form 4] CRYO CELL INTERNATIONAL INC Insider Trading Activity

Rhea-AI Filing Summary

Cryo-Cell International disclosed new equity awards to its VP Finance and CFO, Jill M. Taymans. On January 7, 2026, she received two stock option grants at an exercise price of $3.54 per share. One grant covers 10,000 options that vest one-third on the grant date, one-third on January 7, 2027, and one-third on January 7, 2028. The second grant covers 20,000 options under the Cryo-Cell 2022 Stock Incentive Plan, split into three equal tranches that each require both time-based vesting and the stock reaching average closing prices of at least $6, $8, and $10 per share over 20 consecutive trading days, tied to the first, second, and third anniversaries of the grant. Taymans also reports 45,396 shares of common stock owned directly and multiple prior option awards with expirations ranging from 2026 to 2031.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TAYMANS JILL M

(Last) (First) (Middle)

700 BROOKER CREEK BLVD.

SUITE 1800

(Street)

OLDSMAR FL 34677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRYO CELL INTERNATIONAL INC [ CCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Finance, CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								45,396	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$3.1							06/02/2019	06/02/2026	Common Stock	7,500		7,500	D
Stock Option	$8							09/23/2020(1)	09/23/2027	Common Stock	7,000		7,000	D
Stock Option	$4.62							01/13/2023	01/13/2028	Common Stock	20,000		20,000	D
Stock Option	$5.88							12/22/2023(2)	12/22/2028	Common Stock	10,000		10,000	D
Stock Option	$7.35							01/21/2025(3)	01/21/2030	Common Stock	10,000		10,000	D
Stock Option	$3.54	01/07/2026		A		10,000		01/07/2026(4)	01/07/2031	Common Stock	10,000	$3.54	10,000	D
Stock Option	$3.54	01/07/2026		A		20,000		01/07/2026(5)	01/07/2031	Common Stock	20,000	$3.54	20,000	D

Explanation of Responses:

1. Stock options vest 1/5 per year commencing on September 23, 2020.

2. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.

3. Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.

4. Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.

5. The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.

	/s/ Jill Taymans	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in the 2026 Form 4 for CCEL and what is their role?

The Form 4 reports transactions by Jill M. Taymans, who serves as VP Finance and Chief Financial Officer of Cryo-Cell International Inc. She is an officer but not listed as a director or 10% owner.

What new stock options did Cryo-Cell CFO Jill Taymans receive on January 7, 2026?

On January 7, 2026, Jill Taymans received two stock option awards. One is for 10,000 options at an exercise price of $3.54 per share. The other is for 20,000 options, also at $3.54 per share, granted under the Cryo-Cell 2022 Stock Incentive Plan.

How do the time-based vesting terms work for Jill Taymans’ January 7, 2026 Cryo-Cell options?

For the 10,000-option grant dated January 7, 2026, the options vest one-third upon issuance, one-third on January 7, 2027, and one-third on January 7, 2028, subject to her continued service.

What performance conditions apply to the 20,000 Cryo-Cell options granted to the CFO?

The 20,000-option grant is split into three equal tranches. One tranche vests after the first anniversary and requires the stock to achieve an average closing price of at least $6 over 20 consecutive trading days. The second tranche uses an $8 price level after the second anniversary, and the third tranche uses a $10 level after the third anniversary, in each case requiring continued service.

What other stock option holdings does the Cryo-Cell CFO report in this Form 4?

Jill Taymans reports several existing stock option positions held directly, including 7,500 options at $3.10 expiring on June 2, 2026, 7,000 options at $8.00 expiring on September 23, 2027, 20,000 options at $4.62 expiring on January 13, 2028, 10,000 options at $5.88 expiring on December 22, 2028, and 10,000 options at $7.35 expiring on January 21, 2030, along with the new grants expiring on January 7, 2031.

How many Cryo-Cell common shares does the CFO own after the reported transactions?

Following the reported transactions, Jill Taymans directly owns 45,396 shares of Cryo-Cell International common stock, as shown in the non-derivative holdings table.

Are the January 7, 2026 Cryo-Cell stock option grants to the CFO direct or indirect holdings?

The Form 4 lists all of Jill Taymans’ reported stock option grants, including those dated January 7, 2026, as held with direct (D) ownership, with no separate entity or indirect ownership structure disclosed.